Tiziana Life Sciences PLC's (LON:TILS) founder and chairman Gabriele Cerrone tells Proactive London's Andrew Scott they've filed a patent application around the combination treatment of Nanoparticle - Actinomycin D with its Anti-Interleukin-6 Receptor Monoclonal Antibody for the treatment of coronaviruses.
It follows last week's update that they've acquired the slow release, nano-particle formulation of Actinomycin D which is an antibiotic drug used to treat cancer.
The formulation was developed by Dr Kunwar Shailubhai, the company’s chief executive, during his time at Rasna Therapeutics.
Cerrone says the combination of the drug as an anti-viral along with their anti-inflammatory agent may present an immediate therapeutic option for COVID-19 patients.